Contact and place of performance
Eugene Jackson
Shreveport 71101
RFQ 36C25625Q1470 Question and Answer Reponses The purpose of this amendment is to: Clarify that this requirement is LPTA for brand name or equal to products. Clarify that all CLIN 0001-4026 are all brand name or equal to products and the OEM for the CLINs listed is Werfen. Address the questions submitted in response to the solicitation question deadline of 3pm 09/09/2025. See below Vendor 1: Question: Would it be po...
View moreThe Department of Veterans Affairs, Network Contract Office 16, has issued a combined synopsis and solicitation under solicitation number 36C25625Q1470 for the procurement of blood control reagents. This requirement is being conducted as a Lowest Price Technically Acceptable (LPTA) acquisition for brand name or equal products. The Original Equipment Manufacturer (OEM) for the specified items is Werfen, and the scope includes various clinical line items such as Anti-M reagents. Performance will take place in Shreveport, with a response deadline set for September 12, 2025.
The acquisition is classified under NAICS 325413 for In-Vitro Diagnostic Substance Manufacturing and PSC 6550 for In Vitro Diagnostic Substances, Reagents, Test Kits and Sets. This solicitation includes three attachments: two .docx documents and one SF-30 Amendment, the latter of which was published on September 10, 2025, to clarify product specifications and address vendor questions. Eugene Jackson serves as the point of contact for this federal opportunity.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.